Literature DB >> 10632613

Nerve growth factor (NGF) augments cortical and hippocampal cholinergic functioning after p75NGF receptor-mediated deafferentation but impairs inhibitory avoidance and induces fear-related behaviors.

J Winkler1, G A Ramirez, L J Thal, J J Waite.   

Abstract

Nerve growth factor (NGF) enhances cholinergic functioning in animals with a compromised cholinergic basal forebrain (CBF). Immunotoxic lesions targeting low-affinity NGF receptor (p75NGF receptor)-bearing CBF neurons provide a selective model for testing the effects of NGF on residual cholinergic neurons. Rats received PBS or the immunotoxin 192IgG-saporin (192Sap) intracerebroventricularly at two doses (1 or 2.7 microg) known to produce different degrees of cholinergic deficit. Seven weeks after lesioning, half of each group received either NGF or cytochrome c intracerebroventricularly for 7 weeks. The two doses of 192Sap produced 50 and 80% depletions of choline acetyltransferase (ChAT) activity in the neocortex and hippocampus. NGF produced the greatest increase in ChAT activity in controls, intermediate in low-lesioned, and smallest in highly lesioned animals. NGF-treated animals showed reduced weight gain, hyper-responsiveness to acoustic stimuli, and decreased inhibitory avoidance. Although general motor behavior was affected by neither 192Sap nor NGF in an open field task, highly lesioned rats took longer to reach the platform during water maze testing. Impaired spatial orientation in finding a hidden platform at the previously acquired position was mitigated by NGF. Hypertrophic changes of residual CBF neurons, Schwann cell hyperplasia, and aberrant axonal sprouting around the medulla were observed in NGF-treated animals only, independent of the preexisting lesion. Our results indicate that NGF has a limited capacity to enhance functioning of residual CBF neurons. More importantly, NGF augmented fear-related behaviors and adverse neuroproliferative changes that may restrict its therapeutic use.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10632613      PMCID: PMC6772410     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  59 in total

Review 1.  Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited.

Authors:  J L Cummings; D Kaufer
Journal:  Neurology       Date:  1996-10       Impact factor: 9.910

2.  Short-term and complete reversal of NGF effects in rats with lesions of the nucleus basalis magnocellularis.

Authors:  J Winkler; A E Power; G A Ramirez; L J Thal
Journal:  Brain Res       Date:  1998-03-30       Impact factor: 3.252

3.  Hyperplastic changes within the leptomeninges of the rat and monkey in response to chronic intracerebroventricular infusion of nerve growth factor.

Authors:  P A Day-Lollini; G R Stewart; M J Taylor; R M Johnson; G J Chellman
Journal:  Exp Neurol       Date:  1997-05       Impact factor: 5.330

4.  Time course of cholinergic and monoaminergic changes in rat brain after immunolesioning with 192 IgG-saporin.

Authors:  J J Waite; M L Wardlow; A C Chen; D A Lappi; R G Wiley; L J Thal
Journal:  Neurosci Lett       Date:  1994-03-14       Impact factor: 3.046

5.  Nerve growth factor affects uninjured, adult rat septohippocampal cholinergic neurons.

Authors:  M Fusco; B Oderfeld-Nowak; G Vantini; N Schiavo; M Gradkowska; M Zaremba; A Leon
Journal:  Neuroscience       Date:  1989       Impact factor: 3.590

6.  Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease.

Authors:  M Eriksdotter Jönhagen; A Nordberg; K Amberla; L Bäckman; T Ebendal; B Meyerson; L Olson; M Shigeta; E Theodorsson; M Viitanen; B Winblad; L O Wahlund
Journal:  Dement Geriatr Cogn Disord       Date:  1998 Sep-Oct       Impact factor: 2.959

7.  Heterogeneity and selectivity of the degeneration of cholinergic neurons in the basal forebrain of patients with Alzheimer's disease.

Authors:  S Lehéricy; E C Hirsch; P Cervera-Piérot; L B Hersh; S Bakchine; F Piette; C Duyckaerts; J J Hauw; F Javoy-Agid; Y Agid
Journal:  J Comp Neurol       Date:  1993-04-01       Impact factor: 3.215

8.  Effect of recombinant human nerve growth factor on presynaptic cholinergic function in rat hippocampal slices following partial septohippocampal lesions: measures of [3H]acetylcholine synthesis, [3H]acetylcholine release and choline acetyltransferase activity.

Authors:  P A Lapchak; F Hefti
Journal:  Neuroscience       Date:  1991       Impact factor: 3.590

9.  Behavioral and neurobiological alterations induced by the immunotoxin 192-IgG-saporin: cholinergic and non-cholinergic effects following i.c.v. injection.

Authors:  T J Walsh; R M Kelly; K D Dougherty; R W Stackman; R G Wiley; C L Kutscher
Journal:  Brain Res       Date:  1995-12-08       Impact factor: 3.252

10.  Behavioural, biochemical and histochemical effects of different neurotoxic amino acids injected into nucleus basalis magnocellularis of rats.

Authors:  S B Dunnett; I Q Whishaw; G H Jones; S T Bunch
Journal:  Neuroscience       Date:  1987-02       Impact factor: 3.590

View more
  18 in total

1.  The CB₁ receptor-mediated endocannabinoid signaling and NGF: the novel targets of curcumin.

Authors:  Parichehr Hassanzadeh; Anna Hassanzadeh
Journal:  Neurochem Res       Date:  2012-02-07       Impact factor: 3.996

2.  Cognitive deficit associated with cholinergic and nerve growth factor down-regulation in experimental allergic encephalomyelitis in rats.

Authors:  Giulia D'Intino; Michela Paradisi; Mercedes Fernandez; Alessandro Giuliani; Luigi Aloe; Luciana Giardino; Laura Calzà
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-14       Impact factor: 11.205

Review 3.  Basal forebrain cholinergic dysfunction in Alzheimer's disease--interrelationship with beta-amyloid, inflammation and neurotrophin signaling.

Authors:  Reinhard Schliebs
Journal:  Neurochem Res       Date:  2005 Jun-Jul       Impact factor: 3.996

4.  The cannabinergic system is implicated in the upregulation of central NGF protein by psychotropic drugs.

Authors:  Parichehr Hassanzadeh; Sina Rahimpour
Journal:  Psychopharmacology (Berl)       Date:  2010-12-18       Impact factor: 4.530

5.  The endocannabinoid system and NGF are involved in the mechanism of action of resveratrol: a multi-target nutraceutical with therapeutic potential in neuropsychiatric disorders.

Authors:  Parichehr Hassanzadeh; Elham Arbabi; Fatemeh Atyabi; Rassoul Dinarvand
Journal:  Psychopharmacology (Berl)       Date:  2016-01-18       Impact factor: 4.530

6.  Implication of NGF and endocannabinoid signaling in the mechanism of action of sesamol: a multi-target natural compound with therapeutic potential.

Authors:  Parichehr Hassanzadeh; Anna Hassanzadeh
Journal:  Psychopharmacology (Berl)       Date:  2013-04-27       Impact factor: 4.530

Review 7.  The significance of the cholinergic system in the brain during aging and in Alzheimer's disease.

Authors:  R Schliebs; T Arendt
Journal:  J Neural Transm (Vienna)       Date:  2006-10-13       Impact factor: 3.575

8.  Treatment of spinal cord injury with co-grafts of genetically modified Schwann cells and fetal spinal cord cell suspension in the rat.

Authors:  Shi-Qing Feng; Xiao-Hong Kong; Shi-Fu Guo; Pei Wang; Li Li; Jin-Hua Zhong; Xin-Fu Zhou
Journal:  Neurotox Res       Date:  2005       Impact factor: 3.911

9.  Alleviating effects of Bushen-Yizhi formula on ibotenic acid-induced cholinergic impairments in rat.

Authors:  Xue-Qin Hou; Lei Zhang; Cong Yang; Cui-Ping Rong; Wen-Qing He; Chun-Xia Zhang; Shi Li; Ru-Yu Su; Xiang Chang; Ji-Huan Qin; Yun-Bo Chen; Shao-Xiang Xian; Qi Wang
Journal:  Rejuvenation Res       Date:  2015-04       Impact factor: 4.663

10.  Estrogen effects on high-affinity choline uptake in primary cultures of rat basal forebrain.

Authors:  Katie M Bennett; Courtney Hoelting; Christopher P Martin; James Stoll
Journal:  Neurochem Res       Date:  2008-05-16       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.